4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

More than 40 years after the first implantable cardioverter-defibrillator (ICD) implantation,
sudden cardiac death (SCD) still accounts for more than five million deaths worldwide every …

Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …

Aims The benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform
due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular …

Ischemic heart disease is the most common cause of lethal ventricular arrhythmias and
sudden cardiac death (SCD). In patients who are at high risk after myocardial infarction …

Aims Use of implantable cardioverter‐defibrillators (ICD) for primary prevention of sudden
cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We …

Background The benefit of implantable cardioverter‐defibrillator (ICD) in elderly patients has
been questioned. In the present study, we aimed to analyse the outcome of patients of …

Aims Fragmented QRS complex with visible notching on standard 12-lead
electrocardiogram (ECG) is understood to represent depolarization abnormalities and to …

Implantable cardioverter defibrillator therapy is indicated in a subset of patients with heart
failure with reduced ejection as primary prevention for sudden cardiac death. The advent of …

Background: Identification of patients with nonischemic cardiomyopathy who may benefit
from prophylactic implantation of a cardioverter-defibrillator. We hypothesized that periodic …